• Anteris won full ANSM clearance in France for the DurAVR transcatheter heart valve PARADIGM global pivotal trial in severe calcific aortic stenosis.
• The authorization allows patient recruitment to start at French centers, expanding the trial’s European footprint alongside ongoing US enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606080600PRIMZONEFULLFEED9733169) on June 08, 2026, and is solely responsible for the information contained therein.